Data Insights
No Filter Selected
No Filter Selected
No Filter Selected
No Filter Selected
Efinopegdutide by Merck for Metabolic Dysfunction-Associated Steatotic Liver Disease (MASLD): Likelihood of Approval
Efinopegdutide is under clinical development by Merck and currently in Phase II for Metabolic Dysfunction-Associated Steatotic Liver Disease (MASLD). According...
Efinopegdutide by Merck for Metabolic Dysfunction-Associated Steatohepatitis (MASH): Likelihood of Approval
Efinopegdutide is under clinical development by Merck and currently in Phase II for Metabolic Dysfunction-Associated Steatohepatitis (MASH). According to GlobalData,...
Risk adjusted net present value: What is the current valuation of Merck's Efinopegdutide?
Efinopegdutide is a synthetic peptide commercialized by Merck, with a leading Phase II program in Type 2 Diabetes. According to...